Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma

British Journal of Dermatology

Volumn 144, Issue 2, 2001, Pages 279-287

  Brownbridge, G G ^a   Gold, J ^a   Edward, M ^a   MacKie, R M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Malignant melanoma; MART 1; Polymerase chain reaction; Tyrosinase

Indexed keywords

MELAN A; MONOPHENOL MONOOXYGENASE;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; DISEASE PROGRESSION; HUMANS; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASM CIRCULATING CELLS; NEOPLASM PROTEINS; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0035117128     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.04015.x     Document Type: Article

References (24)

1. Cutaneous malignant melanoma in Scotland: Incidence, survival, and mortality. 1979-1994
2. Stage 2 malignant melanoma in the West of Scotland 1976-85. Prognostic factors for survival
3. Interferon alpha 2b adjuvant therapy on high risk resected cutaneous melanoma
4. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma
5. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
6. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction
7. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay
8. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma
9. The analysis of tyrosinase-specific mRNA in blood samples from melanoma patients by RT-PCR is not a useful test for metastatic tumour progression
10. Detection and quantitation of melanoma cells in the circulation of patients
11. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumour marker in melanoma patients: A clinical two-center study
12. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: Evaluation strategy and correlation with known prognostic markers in 123 melanoma patients
13. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma
14. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma
15. Reverse transcriptasepolymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood
16. Evaluation of tyrosinase mRNA as a tumour marker in the blood of melanoma patients
17. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors
18. Detection of circulating neoplastic cells by reverse transcriptase polymerase chain reaction in malignant melanoma
19. Phenotypic heterogeneity of melanoma - Relation to the differentiation program of melanoma cells
20. Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells
21. Characterisation of a highly invasive and spontaneously metastatic human malignant melanoma cell line
22. Biological properties of human melanoma cells in culture
23. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: A quality control study using real-time quantitative RT-PCR